Adjuvant treatment with cyclosporin A increases the toxicity of chemotherapy for remission induction in acute non-lymphocytic leukemia

Leukemia

Volumn 12, Issue 8, 1998, Pages 1236-1240

  Damiani, D ^a   Michieli, M ^a   Ermacora, A ^a   Russo, D ^a   Fanin, R ^a   Zaja, F ^a   Baraldo, M ^b   Pea, F ^b   Furlanut, M ^b   Baccarani, M ^a,c  

^a Udine University Hospital   (Italy)

^b UNIVERSITY OF UDINE   (Italy)

^c UNIVERSITY HOSPITAL OF UDINE   (Italy)

Author keywords

Acute leukemia; Chemotherapy; Cyclosporin A; Drug resistance; Idarubicin

Indexed keywords

ANTILEUKEMIC AGENT; BILIRUBIN; CYCLOSPORIN A; CYTARABINE; GLYCOPROTEIN P; IDARUBICIN;

ACUTE NONLYMPHOCYTIC LEUKEMIA; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BACTEREMIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DRUG BLOOD LEVEL; FEMALE; GASTROINTESTINAL DISEASE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL; REMISSION;

EID: 17344367589     PISSN: 08876924     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.leu.2401092     Document Type: Article

References (13)

1. Pastan I, Gottesman M. Multiple-drug resistance in human cancer. New Engl J Med 1987; 516: 1388-1393.
2. Weinstein RS, Kuszak JR, Kluskens LF, Coon JS. P-glycoproteins in pathology: the multidrug resistance gene family in humans. Hum Pathol 1990; 21: 34-48.
3. Marie JP, Zittoun R, Sikic BI. Multidrug resistance (mdr1) gene expression in adult acute leukemias: correlations with treatment outcome and in vitro drug sensitivity. Blood 1991; 78: 586-592.
4. Pirker R, Wallner J, Geissler K, Linkesch W, Haas OA, Bettelheim P, Hopfner M, Scherrer R, Valent P, Havelec L, Ludwig H, Lechner K. MDR1 gene expression and treatment outcome in acute myeloid leukemia. J Natl Cancer Inst 1991; 83: 708-712.
5. Campos L, Guyotat D, Archimbaud E, Calmard-Oriol P, Tsuruo T, Troncy J, Treille D, Fiere D. Clinical significance of multidrug resistance P-glycoprotein expression on acute nonlymphoblastic leukemia cells at diagnosis. Blood 1991; 79: 473-476.
6. Michieli M, Damiani D, Geromin A, Michelutti A, Fanin R, Raspadori D, Russo D, Visani G, Dinota A, Pileri S, Tsuruo T, Grandi M, Baccarani M, Tura S. Overexpression of multidrug resistance-associated p170-glycoprotein in acute non-lymphocytic leukemia. Eur J Haematol 1992; 48: 87-92.
7. Savignano C, Geromin A, Michieli M, Damiani D, Michelutti A, Melli C, Fanin R, Baccarani M. The expression of the multidrug resistance related glycoprotein in adult acute lymphoblastic leukemia. Haematologica 1993; 78: 261-263.
8. Wood P, Burgess R, MacGregor A, Liu Yin JA. P-glycoprotein expression on acute myeloid leukaemia blast cells at diagnosis predicts response to chemotherapy and survival. Br J Haematol 1994; 87: 509-514.
9. Guerci A, Merlin JL, Missoum N, Feldmann L, Marchal S, Witz F, Rose C, Guerci O. Predictive value for treatment outcome in acute myeloid leukemia of cellular daunorubicin accumulation and P-glycoprotein expression simultaneously determined by flow cytometry. Blood 1995; 85: 2147-2153.
10. Del Poeta G, Stasi R, Aronica G, Venditti A, Cox MC, Bruno A, Buccisano F, Masi M, Tribalto M, Amadori S, Papa G. Clinical relevance of P-glycoprotein expression in de novo acute myeloid leukemia. Blood 1996; 87: 1997-2004.
11. Michieli M, Damiani D, Ermacora A, Raspadori D, Michelutti A, Grimaz S, Fanin R, Russo D, Lauria F, Masolini P, Baccarani M. P-glycoprotein (PGP) and lung resistance-related protein (LRP) expression and function in leukaemic blast cells. Br J Haematol 1997; 69: 356-365.
12. Berman E, McBride M. Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug resistant leukemia cells. Blood 1992; 79: 3267-3276.
13. Michieli M, Damiani D, Michelutti A, Melli C, Russo D, Fanin R, Baccarani M. p170-dependent multidrug resistance. Restoring full sensitivity to idarubicin with verapamil and cyclosporin A derivatives. Haematologica 1994; 79: 119-126.